The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...

The pipeline of potential treatments is encouraging. Several medicines are in development. Others including GLP-1 agonists like semaglutide (currently used for obesity treatment) are being repurposed ...

Darolutamide, also known as Nubeqa and made by Bayer, is recommended in final draft guidance to treat adults with metastatic hormone-sensitive prostate cancer in combination with androgen deprivation ...

HEMA was convened to be an independent voice guiding best practices in international health technology assessment (HTA). It aims to critically examine and assess new methods, and is a collaboration ...

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults. This ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...

Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over. There are simple ...

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...

Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. There is a simple discount patient ...